checkAd

Revelation Biosciences Inc. and Vanderbilt University Enter Exclusive Worldwide License Agreement

Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today announced an exclusive worldwide license agreement with Vanderbilt University, Nashville TN, USA (Vanderbilt) to develop and commercialize phosphorylated hexaacyl disaccharide (PHAD), for treating or preventing infections.

The license covers potential applications such as prevention or reduction of acquired infections including those resulting from surgery, severe burns, and antibiotic resistance. According to the most recent data published by the Center for Disease Control and Prevention, approximately 687,000 cases of acquired infection in acute care settings resulted in approximately 72,000 deaths. Preclinical studies have shown that treatment with PHAD significantly reduces the duration and severity of infection by augmenting the innate immune response, a form of trained immunity. The license grants Revelation the use of issued US patent 11,389,465.

“We are thrilled to have this license from Vanderbilt University, an institution focused on improving the human condition through pathbreaking discovery and innovation,” said James Rolke, Chief Executive Officer of Revelation. “We are also very excited to move the REVTx-100 program forward with this new license by developing potentially lifesaving treatments for patients in need, thanks in large part to work in the field of trained immunity. Additionally, we believe the extensive preclinical data already generated will allow us to rapidly bring this treatment to the clinic.”

Revelation and Vanderbilt University will continue the prosecution of additional patent applications, which will provide Revelation the exclusive right to use these new technologies once patents are granted.

About Revelation Biosciences Inc.

Revelation Biosciences, Inc. is a life sciences company focused on the development of immunologic based therapies for the prevention and treatment of disease. Revelation has multiple product candidates in development that are based on the well-established biology of PHAD and its effect on the innate immune system. REVTx‑100 is being developed as a prevention and treatment of infection. REVTx‑200 is being developed as an intranasal immunomodulator adjunct to be used in combination with an intramuscular vaccination for more complete immunity. REVTx‑300 is being developed as a potential therapy for the treatment of acute and chronic organ disease including CKD, AKI, and NASH. REVTx‑99b is being developed as a treatment for food allergies. REVDx‑501 is being developed as a rapid diagnostic that can be used to detect IP-10 as a surrogate biomarker for any type of respiratory infection, without the need for specialized instrumentation.

Seite 1 von 3




0 Kommentare
Nachrichtenquelle: Business Wire (engl.)
 |  101   |   |   

Schreibe Deinen Kommentar

Disclaimer

Revelation Biosciences Inc. and Vanderbilt University Enter Exclusive Worldwide License Agreement Revelation Biosciences Inc. (NASDAQ: REVB) (the “Company” or “Revelation”), a life sciences company that is focused on the development of immunologic based therapies for the prevention and treatment of disease, today announced an exclusive worldwide …

Nachrichten des Autors

409 Leser
179 Leser
143 Leser
143 Leser
113 Leser
113 Leser
112 Leser
108 Leser
107 Leser
106 Leser
415 Leser
409 Leser
235 Leser
209 Leser
209 Leser
182 Leser
180 Leser
179 Leser
166 Leser
147 Leser
1142 Leser
766 Leser
589 Leser
515 Leser
501 Leser
492 Leser
472 Leser
464 Leser
464 Leser
434 Leser
7528 Leser
2918 Leser
2431 Leser
2402 Leser
2158 Leser
2102 Leser
1787 Leser
1699 Leser
1586 Leser
1533 Leser